Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting common EGFR mutations in non-small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors.

Journal of the National Cancer Institute - 1 May 2026

Melosky Barbara, Juergens Rosalyn A, Chu Quincy S C, Cheema Parneet, Snow Stephanie, Leighl Natasha B, Blais Normand, Ionescu Diana N, McLeod Deanna, Tsao Ming-Sound, Sacher Adrian, Wheatley-Price Paul, Liu Geoffrey

Abstract excerpt

Mutations of the gene EGFR are frequent oncogenic drivers in non-small cell lung cancer (NSCLC). Third-generation EGFR tyrosine kinase inhibitors, which target common EGFR mutations and the acquired T790M resistance mutation, offer improved inhibitory potency and selectivity. Our review critically assessed the evolving role of these agents for management of NSCLC harboring common EGFR mutations. Multiple global...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Clinical Trials, Phase III as Topic

Share to Indoles

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Source

Identifiers

PMID: 41512290
DOI: 10.1093/jnci/djag008

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting common EGFR mutations in non-small cell lung cancer: a review of global phase 3 trials of third-generation inhibitors.PMID 41512290Read ↗

Current and Emerging Treatment Landscape of Common EGFR-Mutated Advanced Non-small Cell Lung Cancer.Semantic proximity Read ↗

Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences.Semantic proximity Read ↗

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung CancerSemantic proximity Read ↗

Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancerSemantic proximity Read ↗

EGFR mutations in non‑small cell lung cancer: Classification, characteristics and resistance to third‑generation EGFR‑tyrosine kinase inhibitors (Review)Semantic proximity Read ↗

Recent advances in EGFR-targeted therapies for non-small cell lung cancer.Semantic proximity Read ↗

Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.Semantic proximity Read ↗

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance.Semantic proximity Read ↗

Resistance to EGFR Inhibitors in NSCLC: Mechanistic Insights and Emerging Therapies.Semantic proximity Read ↗

Tailored strategies to overcome third-generation TKI resistance in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.